Treatment outcomes of adolescent acute lymphoblastic leukemia treated on Tokyo Children’s Cancer Study Group (TCCSG) clinical trials
详细信息 查看全文
- 作者：Motohiro Kato (1) (2)
Atsushi Manabe (3)
Katsuyoshi Koh (4)
Takeshi Inukai (5)
Nobutaka Kiyokawa (6)
Takashi Fukushima (7)
Hiroaki Goto (8)
Daisuke Hasegawa (3)
Chitose Ogawa (9)
Kazutoshi Koike (10)
Setsuo Ota (11)
Yasushi Noguchi (12)
Akira Kikuchi (13)
Masahiro Tsuchida (10)
Akira Ohara (14) - 关键词：Acute lymphoblastic leukemia ; Adolescents ; Clinical trial
- 刊名：International Journal of Hematology
- 出版年：2014
- 出版时间：August 2014
- 年：2014
- 卷：100
- 期：2
- 页码：180-187
- 全文大小：218 KB
- 参考文献：1. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730-1. CrossRef
2. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP–BFM-ALL 2000 study. Blood. 2011;118:2077-4. CrossRef
3. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP–BFM ALL 2000 study. Blood. 2010;115:3206-4. CrossRef
4. Vrooman LM, Stevenson KE, Supko JG, O’Brien J, Dahlberg SE, Asselin BL, et al. Postinduction dexamethasone and individualized dosing of / Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31:1202-0. CrossRef
5. Tsuchida M, Ohara A, Manabe A, Kumagai M, Shimada H, Kikuchi A, et al. Long-term results of Tokyo Children’s Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-999. Leukemia. 2010;24:383-6. CrossRef
6. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943-5. CrossRef
7. Horibe K, Saito AM, Takimoto T, Tsuchida M, Manabe A, Shima M, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-010): based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol. 2013;98:74-8. CrossRef
8. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30:1663-. CrossRef
9. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009;144:147-6. CrossRef
10. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007;25:813-. CrossRef
11. Pichler H, Reismuller B, Steiner M, Dworzak MN, Potschger U, Urban C, et al. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate: a population-based analysis of 25?years of the Austrian ALL-BFM (Berlin–Frankfurt–Munster) Study Group. Br J Haematol. 2013;161:556-5. CrossRef
12. Pullen J, Shuster JJ, Link M, Borowitz M, Amylon M, Carroll AJ, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia. 1999;13:1696-07. CrossRef
13. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11:429-8. CrossRef
14. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution. BCR Breakpoint Prognostic Significance. Leukemia. 1991;5:196-.
15. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646-4. CrossRef
16. Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-0. CrossRef
17. de Bont JM, Holt B, Dekker AW, van der Does van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in The Netherlands. Leukemia. 2004;18:2032-. CrossRef
18. Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children’s oncology group. J Clin Oncol. 2009;27:5189-4. CrossRef
19. Pui CH, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol. 2011;29:386-1. CrossRef
20. Chessells JM, Hall E, Prentice HG, Durrant J, Bailey CC, Richards SM. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998;12:463-3. CrossRef
21. Nakano TA, Hunger SP. Blood consult: therapeutic strategy and complications in the adolescent and young adult with acute lymphoblastic leukemia. Blood. 2012;119:4372-. CrossRef
22. Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children’s Cancer Study Group L95-14 protocol. J Clin Oncol. 2005;23:6489-8. CrossRef
23. Manabe A, Ohara A, Hasegawa D, Koh K, Saito T, Kiyokawa N, et al. Significance of the complete clearance of peripheral blasts after 7?days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children’s Cancer Study Group Study L99-15. Haematologica. 2008;93:1155-0. CrossRef
24. Hasegawa D, Manabe A, Ohara A, Kikuchi A, Koh K, Kiyokawa N, et al. The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study. Pediatr Blood Cancer. 2012;58:23-0. CrossRef
25. Kato M, Koh K, Manabe A, Saito T, Hasegawa D, Isoyama K, et al. No impact of enhanced early intensification with intermediate-risk pediatric acute lymphoblastic leukemia: results of randomized trial TCCSG study L99-15. Br J Haematol. 2014;164:376-3. CrossRef
26. Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477-9. CrossRef
27. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-. CrossRef
28. Gupta V, Richards S, Rowe J, Acute Leukemia Stem Cell Transplantation Trialists-Collaborative G. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood. 2013;121:339-0. CrossRef
29. Wang L, Wang Y, Tang W, Dou HB, Shan JH, Hu J. The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission. Int J Hematol. 2013;98:569-7. CrossRef
30. Isakoff MS, Freyer DR, Bleyer A. Young adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen do not need a bone marrow transplant in first remission. Blood. 2013;121:5253-. CrossRef
31. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731-. CrossRef
32. Stiller CA, Benjamin S, Cartwright RA, Clough JV, Gorst DW, Kroll ME, et al. Patterns of care and survival for adolescents and young adults with acute leukaemia: a population-based study. Br J Cancer. 1999;79:658-5. CrossRef
33. Nachman J. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2005;130:166-3. CrossRef
34. Bleyer A, Siegel SE, Coccia PF, Stock W, Seibel NL. Children, adolescents, and young adults with leukemia: the empty half of the glass is growing. J Clin Oncol. 2012;30:4037-. CrossRef
35. DeAngelo DJ. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2005;2005:123-0.
36. Sakura T, Hayakawa F, Yujiri T, Aoyama Y, Kondo E, Fujimaki K, et al. Outcome of pediatric-type therapy for Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA): a study by the Japan adult leukemia study Group (JALSG ALL202-U study). Blood. 2012;120:1464 (ASH Annual Meeting Abstracts). - 作者单位：Motohiro Kato (1) (2)
Atsushi Manabe (3)
Katsuyoshi Koh (4)
Takeshi Inukai (5)
Nobutaka Kiyokawa (6)
Takashi Fukushima (7)
Hiroaki Goto (8)
Daisuke Hasegawa (3)
Chitose Ogawa (9)
Kazutoshi Koike (10)
Setsuo Ota (11)
Yasushi Noguchi (12)
Akira Kikuchi (13)
Masahiro Tsuchida (10)
Akira Ohara (14)
1. Department of Pediatrics, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
2. Department of Cell Therapy and Transplantation Medicine, The University of Tokyo, Tokyo, Japan
3. Department of Pediatrics, St. Luke’s International Hospital, Tokyo, Japan
4. Department of Hematology/Oncology, Saitama Children’s Medical Centre, Saitama, Japan
5. Department of Pediatrics, University of Yamanashi, Kofu, Japan
6. Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan
7. Department of Pediatrics, Tsukuba University, Tsukuba, Japan
8. Division of Hemato-oncology/Regenerative Medicine, Kanagawa Children’s Medical Center, Yokohama, Japan
9. Division of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan
10. Department of Hematology/Oncology, Ibaraki Children’s Hospital, Mito, Japan
11. Department of Pediatrics, Teikyo University Chiba Medical Center, Ichihara, Japan
12. Department of Pediatrics, Japanese Red Cross Narita Hospital, Narita, Japan
13. Department of Pediatrics, Teikyo University, Tokyo, Japan
14. Department of Pediatrics, Toho University, Tokyo, Japan - ISSN：1865-3774
文摘
There is no standard treatment for adolescents aged 15?years or older with acute lymphoblastic leukemia (ALL), although this age group has been reported as having a poorer prognosis compared to younger patients. We retrospectively analyzed the outcomes of three consecutive Tokyo Children’s Cancer Study Group ALL trials (1995-006) of 373 patients aged 10?years or older, with particular focus on adolescents aged 15-8?years (older-adolescents n?=?41), compared to those aged 10-4?years (younger-adolescents n?=?332). The probability of event-free survival at 8?years was 67.5?±?7.4?% for the older-adolescents and 66.5?±?2.6?% for the younger-adolescents (p?=?0.95). Overall survival was 70.7?±?7.1?% for the older-adolescents and 74.3?±?2.4?% for the younger-adolescents (p?=?0.48). The differences between groups in relapse incidence, non-relapse mortality, and death rate during induction were not statistically significant, although the older-adolescents trended towards a higher frequency of having stem-cell transplantation during the first remission. In conclusion, our treatment strategy, which consists of intensive induction and block-type consolidation, provided improved outcomes for patients aged 15-8?years, comparable to those for patients aged 10-4?years.